State-of-the-Art
Pharmaceutical Intelligence

Competitive Intelligence·Search & Evaluation·Trial Outcome Forecasting·Asset Due Diligence·Portfolio Optimization

Today's approach can't answer your billion-dollar questions.

Which drug candidates outperform the standard of care?: It takes a month to gather the safety and efficacy data. Ten drugs from China are missing. Results weren't found for 50 drugs.
What is the likelihood that this drug gets approved?: Current predictions are based on broad benchmarks that are not applicable to your asset.
How much is this drug worth?: NPV models are predicated on many fragile assumptions that each rely on incomplete data.
Which drug programs should we discontinue and which should we keep?: A drug with a similar mechanism was discontinued for toxicity, but your risk assessment wasn't updated, leading to unnecessary investment.

Gosset

Monitor

Gosset is the only platform with safety, efficacy, trial design, and biomarker data for every trial with disclosed results.
Generate comprehensive landscapes for niche and nuanced indications with IP, pricing, and detailed development status.
Efficiently understand each drug's market positioning.
Get up to speed on the standard of care with reports backed by drug labels and current treatment guidelines.

Source

Identify drug candidates that outperform the standard of care.
Generate the short list of legitimate acquisition targets from among hundreds of pipeline assets
Assess target validation, competitive crowding, and market potential.
Get sensitive and specific drug lists from complex, specific queries.

Predict

Validated, calibrated, and accurate predictions of the probability of technical and regulatory success of clinical trials
Clinical trial completion date forecasting that is 47 days more accurate than sponsors' forecasts
Custom models tuned to your company's historical trials

Validate

Leverages your proprietary data alongside Gosset's knowledge graph
Target validation that draws from data on competing and discontinued drugs
Safety, efficacy, and benchmarking against competitors
Total addressable market calculations informed by comprehensive pricing data and detailed epidemiology
Patent portfolio, composition of matter expiration, regulatory designations, and exclusivity timelines
Detailed, evidence-based risk analysis

Prioritize

Personalized recommendations based on current pipeline, investment resources, and opportunities
Accounts for cumulative time, cost, and likelihood of success in all remaining trials for each asset
Constantly monitors competitor development events and updates risk assessments

See the evidence behind your next decision.

Get a walkthrough tailored to the questions you're working on.